Michael G. Silverman

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6K citations · Full text

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Eri Kato, Michael G. Silverman, Ofri Mosenzon et al. · Circulation · 2019 · 550 citations

Use of Coronary Artery Calcium Testing to Guide Aspirin Utilization for Primary Prevention: Estimates From the Multi-Ethnic Study of Atherosclerosis

Michael D. Miedema, Daniel Duprez, Jeffrey R. Misialek et al. · Circulation Cardiovascular Quality and Outcomes · 2014 · 235 citations · Full text

The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA)

Mahmoud Al Rifai, Michael G. Silverman, Khurram Nasir et al. · Atherosclerosis · 2015 · 204 citations · Full text

Obesity, Metabolic Syndrome, Metabolic Associated Steatohepatitis +14

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial

Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · American Heart Journal · 2018 · 179 citations

Metabolic Syndrome, Hypertension, Cardiovascular Disease +8